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Introduction
Diabetic retinopathy (DR) is the leading cause of blindness
among patients 25–74 years old in industrialized countries. In the
US alone, there are 29 million Americans living with diabetes
mellitus (DM). The diagnosis, prevention, and treatment of DR
thus represent a formidable challenge to the health-care system.
Vigilant awareness of the continually evolving landscape of
medical knowledge is critical to stemming this crisis. This review
aims to provide important clinical updates in the management of
DR.

Update on diagnosis
The cause of DR is multifactorial, and the primary contributor
likely is chronic capillary non-perfusion and retinal ischemia.
The signaling molecules insulin-like growth factor-1, plateletderived growth factor, angiopoietin, and most importantly vascular
endothelial growth factor (VEGF) all play a role in the subsequent
development of microangiopathy1. Recent evidence also suggests that neurodegeneration is an early event in the pathogenesis
of DR2,3. From a clinical standpoint, it is clear that the primary
driving factor in this pathogenesis is uncontrolled blood glucose
levels, with blood pressure and blood lipid composition also
playing important roles. The diagnosis of DR remains clinical
in nature. The gold standard for diagnosis is a dilated eye exam
and serial fundus photos. Careful attention should be given to
fundoscopic features of retinopathy, including microaneurysms,
intraretinal hemorrhage, hard exudates, venous beading, intraretinal microvascular anomalies (IRMAs), and, in the proliferative
form, signs of neovascularization (NV). Several emerging technologies have demonstrated promise in assisting with the diagnosis of sight-threatening retinopathy. Researchers in collaboration
with Google recently created a deep learning arti cial neural
network trained to detect retinopathy based on fundoscopic
images and achieved sensitivity of 97.5–96.1% and speci city of
93.4–93.9% in detecting referable disease. In a hypothetical
population with a prevalence of 8%, this translates to impressive positive and negative predictive values of 99.8% and 99.6%,
respectively4. Such automated systems hold the potential of
offsetting the surge in demand for screening.

Update on imaging
Imaging modalities, especially optical coherence tomography
(OCT) and uorescein angiography (FA), now play a crucial
role in the diagnosis and management of complications of DR,
particularly for diabetic macular edema (DME) and subtle
NV, respectively. Newer modalities of OCT, including optical
coherence tomography angiography (OCTA), hold the promise
of further expanding the role of imaging. By using variation in
phase and intensity of a light signal to infer vascular structures5,
OCTA is able to resolve vascular details not achievable by conventional FA, such as the deep and super cial capillary plexus6.
Several authors have argued that OCTA is at least equal to FA in
terms of ability to detect macular complications of DM, as it can
detect areas of IRMA and NV7. Other microvascular changes seen
on OCTA, speci cally decreasing capillary density, branching
complexity, and increasing average vascular caliber, are all associated with worsening DR (Figure 1)8. Intriguingly, some forms
of retinal edema may be visible on OCTA but will not appear

Figure 1. Optical coherence tomography angiography image
of a left eye in a patient with severe non-proliferative diabetic
retinopathy, displaying enlargement and irregularity of the
foveal avascular zone, and temporal capillary dropout.

as uid pockets on OCT or late staining on FA9. Important
drawbacks of the technology are the small eld of view and
relative de ciency in detection of microaneuryms9.

Update on glycemic control and systemic factors
The Diabetes Control and Complications Trial (DCCT) and
United Kingdom Prospective Diabetes Study demonstrated that
glycemic control reduces microvascular complications for type 1
and type 2 diabetics, respectively10. A recent 30-year follow-up of
the DCCT, and more speci cally the Epidemiology of Diabetes
Interventions and Complications study, also showed the importance of hemoglobin A1c (HbA1c) control, revealing a 50% risk
reduction of retinopathy progression in intensive glycemic control patients, despite a subsequent increase (and corresponding
decreasing in standard control patients) to a mean HbA1c value
of 8%11,12. The Diabetic Retinopathy Clinical Research Network
(DRCR.net) recently released the results of Protocol M, which
showed that the addition of personalized risk assessments and
education about glycemic control during ophthalmic of ce visits
did not affect glycemic control13.
The Action to Control Cardiovascular Risk in Diabetes Followon (ACCORDION) group also recently released follow-up data
of the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial. Four-year outcomes of patients with type 2 DM
were compared between a standard therapy group (goal HbA1c
7.0–7.9%, mean HbA1c 7.7% during the study) and intensive
glucose control group (goal HbA1c <6%, mean HbA1c 6.4%).
Despite normalization after the study period, only 5.8% of

intensive control patients had a three-step Early Treatment
Diabetic Retinopathy Study (ETDRS) worsening, compared
with 12.7% of standard therapy patients14. This interesting result
suggests that there is a form of metabolic memory in diabetic
patients, which confers a protective effect of even short periods
of intense glycemic control. The ACCORDION group also looked
at the effects of blood lipid composition and blood pressure,
showing that intensive blood pressure control had no effect on
DR progression but that treatment with feno brate did show a
reduction in progression. The Feno brate on the Need for Laser
Treatment for Diabetic Retinopathy (FIELD) study echoed these
ndings, showing that patients taking feno brate had a reduced
need for laser therapy. Interestingly, non-lipidic mechanisms
appear to have a more central role in this bene cial effect than
lipidic mechanisms15,16.
It is important to note, however, that the ACCORD study was
halted prematurely when it appeared that all-cause mortality was
greater in intensive glycemic control patients. It is apparent that
cardiovascular disease was the primary cause of mortality, but the
exact reason for this discrepancy remains unclear. This effect was
not seen in similar studies, but polypharmacy has been suggested
as a possible factor17. Based on the above studies, it is advisable
to aim for an HbA1c of less than 7% and to avoid polypharmacy.
Importantly though, glycemic goals need to be carefully individualized on the basis of the presence of additional comorbidities,
expected longevity, and any other relevant factors.

Update on surgery and vitreolysis
Vitreoretinal surgery is the standard treatment of several ocular
complications of DR. The treatment of choice for non-clearing
vitreous hemorrhage remains pars plana vitrectomy. Diabetics
can experience macular edema from vitreous traction or epiretinal membranes, both of which are surgically treated. Tractional
retinal detachments (TRDs) threatening the macula and combined
tractional-rhegmatogenous retinal detachments should be surgically repaired18, although more peripheral TRDs often can be
carefully observed19. Diabetic patients with vitreomacular traction (VMT) may also bene t from surgical intervention. The
DRCR.net investigated the ef cacy of pars plana vitrectomy and
membrane peeling for patients with VMT and DME in Protocol D.
The study found that nearly 40% of patients had a visual gain of at
least 10 letters but that 22% had a worsening of at least 10 letters.
This result was concurrent with a host of surgical complications
like endophthalmitis (1.1%), vitreous hemorrhage (5.7%), and
retinal detachment (3.4%)20. The recent advent of small-gauge
vitrectomy may help stem these complications and potentially tip
the balance toward earlier surgical intervention.
It has been shown that the presence of a posterior vitreous
detachment (PVD) reduces the risk of proliferative diabetic
retinopathy (PDR) development, likely because the posterior
hyaloid and vitreous act as a scaffold for NV. Ocriplasmin is a proteolytic enzyme agent intended to non-surgically induce a PVD.
A trial to investigate its use in patients with diabetes is under way21.
Non-clearing vitreous hemorrhage is a common complication of
neovascular disease that is also treated surgically. The original

Diabetic Retinopathy Vitrectomy Study showed that early vitrectomy (that is, within six months compared with more than one
year) can be useful, especially for type 1 diabetics22. Though the
risks and bene ts of vitrectomy must be weighed in each case,
earlier surgery can be helpful in immediately restoring vision,
inducing a PVD, and providing pan-retinal photocoagulation to
reduce disease burden23. Anti-VEGF agents have proven useful in
the management of vitreous hemorrhage and have been shown to
reduce the eventual need for vitrectomy24. Nevertheless, vitrectomy
still has a role to play for non-clearing hemorrhage.
Retina surgeons have also incorporated the use of intravitreal
VEGF inhibitors when repairing TRDs. In case series, preoperative anti-VEGF injections have been shown to improve
outcomes in patients with TRD by regressing active retinal
NV and decreasing the likelihood of perioperative bleeding25.
However, use of these agents has also been reported to exacerbate TRDs via the ‘crunch’ phenomenon, whereby brovascular
contraction occurs26, making it more dif cult to separate tissue planes27. Newer techniques and devices have the potential to
further improve the outcomes in patients with TRDs. Bimanual
dissection techniques with chandelier lighting or an illuminated
pick can be effective in repair of complex detachments and
peeling membranes28. Additionally, mixed-gauge vitrectomy, with
27-gauge instruments inserted through 24-gauge cannulas, can
permit access to more of the retinal periphery in these complex
cases29.

Update on laser
The landmark Diabetic Retinopathy Study demonstrated a
reduction in severe vision loss in patients with high-risk PDR
following prompt treatment with panretinal photocoagulation
(PRP)30. The ETDRS originally demonstrated a 50% reduction in moderate vision loss in patients with clinically signi cant
diabetic macular edema (CSME) who underwent immediate focal
laser photocoagulation31. Moreover, among patients with PDR or
severe non-proliferative diabetic retinopathy (NPDR), combined
focal and scatter photocoagulation reduced severe vision loss
by 50%. The DRCR.net Protocol K results revealed that among
patients with a reduction in CSME 16 weeks after focal/grid laser
treatment, 23–63% will continue to improve without further
treatment32. PRP remains a mainstay of treatment for proliferative disease. Recently, the results of DRCR.net Protocol S were
released, demonstrating that the anti-VEGF agent ranibizumab
was non-inferior to PRP for the treatment of PDR. At two years of
follow-up, about 53% of patients in the PRP group also received
intravitreal ranibizumab for coexisting DME, demonstrating
that combination treatment can be helpful in these situations33.
How this will affect clinical practice patterns, especially in light
of concerns surrounding cost and the inconvenience of regular
intravitreal injections, remains to be seen. And while focal laser
is still used by many practitioners, anti-VEGF agents have largely
displaced it as the primary treatment of DME. There continues
to be research into use of focal laser, especially in the form of
non-damaging, or subthreshold, laser therapy, although to date
this form has shown only marginal bene t compared with
conventional laser34. Although many physicians currently use
non-damaging laser, there remains to be a clear consensus on its
preferred use.

Update on pharmacologics: ranibizumab
As mentioned previously, anti-VEGF agents are revolutionizing the management of DR. Intravitreal VEGF inhibitors are the
rst-line agents to treat center-involving DME, and these agents
have a growing use in control of proliferative disease as well.
Ranibizumab (Lucentis, Genentech, South San Francisco, CA,
USA) is the antigen-binding fragment of a humanized murine
recombinant monoclonal antibody to VEGF-A35 and is US Food
and Drug Administration (FDA)-approved for the treatment of
DME and DR at a dose of 0.3 mg monthly.
The Ranibizumab for Diabetic Macular Edema (RIDE and
RISE) trials investigated the use of monthly ranibizumab at two
doses—0.5 and 0.3 mg—for the treatment of DME36. A secondary
analysis of these data also examined the progression of DR
in these patients using the diabetic retinopathy severity score
(DRSS)37. In patients with NPDR or PDR, there was an at least
three-step improvement in 15% and 13.2% of patients using
monthly 0.3 or 0.5 mg injections at 36 months, respectively37.
Only 3.3% of patients in the sham group achieved this result. The
probabilities of progression to PDR in these patients were 39%
in the sham group and 18.3% and 17.1% in the 0.3 and 0.5 mg
groups, respectively.
Five hundred patients from RIDE and RISE were then offered
ranibizumab 0.5 mg as needed, and outcomes at 48 months were
examined. At 48 months, 11.2% and 7.6% of patients in the
0.3 and 0.5 mg groups achieved an at least three-step DRSS
improvement, respectively. The sham with crossover group, by
comparison, saw this improvement in only 4.8%. Additionally,
an at least two-step worsening occurred in 2.5% and 11.3% of
ranibizumab and sham patients, respectively. Finally, patients
originally in the ranibizumab groups had overall lower risk of
PDR development than the sham group, a nding which persisted to month 5437. An additional secondary analysis looked at
FA results in the sham group and showed that when these patients
were switched to ranibizumab, retinal non-perfusion was halted38.
Overall, RIDE and RISE stressed the importance of early and
regular therapy with ranibizumab.
The DRCR.net, mentioned above, also examined results of
treatment of DME with combinations of laser, steroids, and antiVEGF in Protocol I. The study was a prospective randomized trial
which divided patients with DME into four groups: sham injection plus focal laser (L), triamcinolone injection plus focal laser
(T+L), ranibizumab with prompt laser (R+pL), and ranibizumab
with deferred laser (R+dL)39. Further analysis then separated
these groups into patients with and without PDR at the time of
randomization40. For patients without PDR at baseline, worsening of retinopathy at 36 months was reported in 7%, 18%, 23%,
and 37% of R+dL, R+pL, L, and T+L groups, respectively.
Among patients with PDR at baseline, worsening of retinopathy at
36 months was reported in 18%, 21%, 40%, and 12% among the
same respective groups. Additionally, patients receiving injections of
any kind (ranibizumab or triamcinolone) had lower rates of vitreous
hemorrhage and were less likely to require PRP. The results are

strong evidence that ranibizumab can help prevent progression of
retinopathy.
As mentioned previously, DRCR.net Protocol S also showed
that ranibizumab was non-inferior to PRP in patients with highrisk PDR33. Additional 2016 data showed that patients with PDR
treated with ranibizumab showed less progression than patients
treated with PRP41. Ranibizumab was recently approved by the
FDA for treatment of all forms of DR. It remains to be seen how
the results of Protocol S combined with this approval will affect
clinical practice patterns.

Update on pharmacologics: a ibercept
A ibercept (Eylea, Regeneron, Tarrytown, NY, USA), another
widely used agent, is a fusion protein of the human IgG Fc region
and the extracellular VEGF receptor ligand binding region, which
binds to VEGF-A, VEGF-B, placental growth factor-1 (PlGF-1),
and PlGF-235. It is FDA-approved for the treatment of DME and
DR in patients with DME at a dose of 2 mg every eight weeks
after ve initial monthly injections. It has been studied recently in
the Intravitreal A ibercept for Diabetic Macular Edema (VISTA
and VIVID) trials. In these trials, a ibercept was compared with
focal laser for the treatment of DME42. These studies demonstrated the superiority of a ibercept over laser in terms of visual
acuity improvement and at least two-step improvement in DRSS.
Patients were separated 1:1:1 into groups receiving focal laser,
2 mg of intravitreal a ibercept every four weeks, or 2 mg every
eight weeks. Both injection groups initially received ve months of
monthly a ibercept injections. Patients in either a ibercept group
were three times more likely to achieve at least two-step DRSS
improvement than patients in the laser group. In both studies,
baseline DRSS was correlated with the likelihood of at least
two-step DRSS improvement.
A recent publication from the DRCR.net43 evaluated eyes
enrolled in Protocol T and reviewed how their DRSS changed
after treatment with a ibercept, bevacizumab, or ranibizumab.
In this analysis, all three agents were effective in reducing DR.
However, in the subset of eyes that had PDR at baseline,
a ibercept was more effective in regressing the PDR than
bevacizumab or ranibizumab.

Update on pharmacologics: bevacizumab
Bevacizumab (Avastin, Genentech) is a full-length humanized
murine monoclonal antibody that binds to VEGF-A35. It is not
FDA-approved for the treatment of DR or DME. The intravitreal bevacizumab or laser therapy in the management of diabetic
macular edema (BOLT) study examined the ef cacy of bevacizumab versus focal laser for DME. Patients in the bevacizumab
group showed signi cant best-corrected visual acuity (BCVA)
improvement over patients in the laser group44. ETDRS retinopathy levels were also included and showed that patients in the
bevacizumab arm trended toward DR reduction, although this
effect was not statistically signi cant. This is likely due to the
relatively small number of patients enrolled in the study. A recent
comparative effectiveness randomized clinical trial conducted

by the DRCR.net compared bevacizumab with ranibizumab and
a ibercept for DME and found that all three agents are effective
treatments, and this was con rmed on two-year follow-up45.

Anti–vascular endothelial growth factor summary
These and earlier trials of anti-VEGF agents are evidence that
early and regular anti-VEGF treatment can halt and sometimes
reverse DR. The reason for reversal is still unclear, and elucidation of this mechanism may open the door to new therapies.
Given that capillary non-perfusion and retinal ischemia may be
the primary contributors to DME and DR progression at baseline, it is possible that halting non-perfusion results in a reversal
of the disease in some patients37. Knowing which patients will or
will not bene t most from anti-VEGF treatment continues be an
active area of research. It has been suggested that early positive
response to anti-VEGF injections predicts outcome at three
months46. Conversely, recent OCTA data showed that deep
capillary plexus damage predicts poor response to treatment47. As
with any invasive therapy, careful consideration of the risks and
bene ts of repeated intravitreal injections is necessary for each
patient. These risks include serious ophthalmic complications
such as endophthalmitis and retinal detachment as well as
potential systemic complications such as hypertension, proteinuria, impaired wound healing, and increased risk of cardiovascular
events48.

Update on dexamethasone and uocinolone acetonide
Despite the dominance of anti-VEGF agents, there is still a role
to play for intravitreal corticosteroids. Steroids work by inhibiting leukostasis, enhancing barrier function of tight junctions, and
mitigating release of local in ammatory factors, including VEGF49.
The Macular Edema: Assessment of Implantable Dexamethasone
in Diabetes (MEAD) study examined the effectiveness of a dexamethasone implant versus sham for the treatment of DME. The
implant groups (0.7 and 0.35 mg) had higher percentages of patients
achieving at least 15 ETDRS letters gained at 3-year follow-up
compared with the sham group (22%, 18%, and 12%, respectively).
A pooled analysis of the MEAD study showed that patients in either
implant group had a 12-month delay in two-step DR progression
(36 versus 24 months) compared with sham patients50. As with
most steroid treatments, development of cataract and intraocular
pressure (IOP) elevation were the most common side effects.
Fluocinolone acetonide (Iluvien, Alimera Sciences, Alpharetta,
GA, USA) is another corticosteroid implant that has treatment
bene t for at least three years. The Fluocinolone Acetonide in
Diabetic Macular Edema study evaluated low-dose (0.2 μg per
day) and high-dose (0.5 μg per day) uocinolone implants in
patients with DME who had received at least one laser treatment.
At 36 months, 33% and 31.9% of patients in the low-dose and
high-dose groups, respectively, had an improvement of 15 ETDRS
letters or more, compared with 21.4% of sham patients. Of patients
with a history of DME at least three years, 34% and 28.8%
of low- and high-dose patients, respectively, gained 15 ETDRS
letters or more, compared with 13.4% of sham patients. Moreover,
an at least two-step improvement in DRSS occurred in 13.7% of
low-dose and 10.1% of high-dose patients compared with 8.9% of
sham patients. As with other steroid therapies, side effects included
cataract and IOP elevation. IOP elevation was severe enough to

require glaucoma tube shunt placement in less than 5% of low-dose
patients and 8% of high-dose patients51.
The results of DRCR Protocol U will also soon be available.
This study will assess the short-term effects of combination
intravitreal dexamethasone and ranibizumab therapy in eyes with
persistent DME despite prior anti-VEGF therapy compared with
continued anti-VEGF therapy alone.

Summary of pharmacologic agents
The continued takeaway of these recent studies on pharmacologic agents is that early treatment of DME in NPDR or PDR is
vital to halt and sometimes reverse retinopathy. De-escalation of
anti-VEGF treatment is sometimes possible without compromising initial gains, although this is more often the case when therapy
has been initiated early. Corticosteroids are beginning to take a
place as second-line therapy for patients unresponsive to antiVEGF agents or focal laser or both. This is especially applicable for
pseudophakic patients who have passed a steroid IOP challenge.

Conclusions
Despite the remarkable gains we have made in the treatment
of DR and its complications, the primary strategy against this
disease should be the ardent prevention of diabetes whenever possible. If diabetes is already present, tight glycemic control is the
most important modality to prevent or control retinopathy, and
control of other systemic factors such as lipid levels and blood
pressure also plays an important role. New diagnostic approaches
and imaging modalities may aid in capturing referable retinopathy at earlier stages. Once retinopathy develops, early and regular treatment is crucial to prevent permanent vision loss. While
there remains a place for laser and incisional surgery, the role of
pharmaceutical agents has expanded in recent years. Anti-VEGF
agents have become the rst-line agents for the treatment of
center-involved DME. In addition, intravitreal VEGF inhibitors
have been proven to be effective in regressing DR. Inhibition of
VEGF has resulted in an effective treatment to preserve vision in
patients with DR. Future treatment strategies might focus on less
invasive delivery methods or alternative therapeutic targets. In
the early stages of DR, when neurodegeneration plays an important role, intravitreal anti-VEGF injections may represent an
overly aggressive approach. In these situations, topically delivered therapies, such as endogenous neuroprotective substances,
hold exciting promise52. Along with the continued vigilance
of clinicians, the expanding armamentarium of diagnostic and
therapeutic options for DR will be an invaluable tool in the ght to
reduce the impact of this devastating disease.
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